What is MOUNJARO® 12.5mg KwikPen®
The MOUNJARO® 12.5mg KwikPen® is a multi-use injection device designed to provide 12.5 mg tirzepatide in 0.6 mL once weekly. This intermediate strength is used as a titration step before the maximum 15 mg dose. Each pen contains 2.4 mL of solution (50 mg total), equivalent to four fixed injections. The product is supplied as a clear, colourless to slightly yellow solution for subcutaneous use in the abdomen, thigh, or upper arm.
- Dose per injection: 12.5 mg tirzepatide (0.6 mL)
- Total pen content: 50 mg/2.4 mL (20.8 mg/mL)
- Number of doses: 4
- Administration: Subcutaneous
- Injection sites: Abdomen, thigh, upper arm
What is the Administration Protocol for MOUNJARO® 12.5mg KwikPen®
The 12.5 mg pen serves as a transitional dose to improve tolerability during escalation. It is administered weekly on a fixed schedule.
- Initiation: Therapy begins at 2.5 mg weekly, with stepwise titration
- Escalation: 12.5 mg used as step between 10 mg and 15 mg
- Maintenance: Doses may be 5, 10, 12.5, or 15 mg depending on tolerance
- Missed dose instructions:
- ≤4 days late: inject promptly
- 4 days late: skip dose, resume schedule
- Administration technique:
- Attach new needle before each use
- Dial to 1 (=0.6 mL)
- Inject subcutaneously, hold for 5 seconds until display shows 0
- Rotate injection sites with each dose
What are the Indications for MOUNJARO® 12.5mg KwikPen®
The product is indicated for metabolic control and weight reduction in adults.
- Indications:
- Adults with type 2 diabetes mellitus
- Adults with BMI ≥30 kg/m²
- Adults with BMI ≥27 to <30 kg/m² with comorbidities (hypertension, dyslipidaemia, OSA, cardiovascular disease, prediabetes)
- Contraindications:
- Hypersensitivity to tirzepatide or excipients
- Precautions:
- Severe gastrointestinal disease
- Prior pancreatitis
- Adverse effects:
- Common: nausea, vomiting, diarrhoea, abdominal pain, constipation
- Hypoglycaemia with insulin or sulphonylureas
- Injection-site reactions up to 8%
- Gallbladder events in a small proportion
- Rare: pancreatitis, allergic reactions
What is the composition of MOUNJARO® 12.5mg KwikPen®
The formulation combines tirzepatide with stabilizing excipients.
- Active substance: Tirzepatide 12.5 mg/0.6 mL
- Total pen content: 50 mg/2.4 mL
- Concentration: 20.8 mg/mL
- Excipients: Benzyl alcohol (~5.4 mg/dose), disodium hydrogen phosphate heptahydrate, glycerol, phenol, sodium chloride, sodium hydroxide, hydrochloric acid, water for injections
- Sodium content: <1 mmol sodium per dose
- Appearance: Clear, colourless to slightly yellow solution
What Comes in the MOUNJARO® 12.5mg KwikPen® Package
The pack includes the device and required documentation but excludes needles.
- Presentation: 2.4 mL KwikPen® with 4 doses
- Pack sizes: 1 or 3 pens per carton
- Needles: Not included in pack
- Documentation: Instructions for Use and Patient Leaflet
Does MOUNJARO® 12.5mg KwikPen® cause side effects?
Side effects occur most frequently in the gastrointestinal system.
- Very common: Nausea, vomiting, diarrhoea, constipation, abdominal pain
- Hypoglycaemia risk: Increased with sulphonylurea or insulin
- Injection-site reactions: Mild, up to 8% incidence
- Gallbladder-related events: Occur in ≤2%
- Rare: Acute pancreatitis, hypersensitivity reactions
- Laboratory findings: Increased amylase and lipase
How should MOUNJARO® 12.5mg KwikPen® be stored?
Storage requirements are strict to maintain potency.
- Unopened pens: Refrigerate at 2–8 °C
- Do not freeze; discard if frozen
- After opening: Store at ≤30 °C for up to 30 days
- Discard after 30 days even if liquid remains
- Needles: Remove after each injection, discard in sharps container
- Safety: Keep away from children